Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 52-week safety study of bicifadine SR in chronic neuropathic pain due to diabetic peripheral neuropathy
2007-007764-14Phase 2Terminated
- Sponsor
- XTL Biopharmaceuticals Ltd.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bicifadine in Neuralgia and diabetic polyneuropathy (DPN), sponsored by XTL Biopharmaceuticals Ltd. Primary endpoint: Safety assessments. Started Apr 2008; status: terminated.
02
Drugs
bicifadine
03
Conditions
Neuralgiadiabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2007-007764-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007764-14.